Schizophrenia
Conditions
Keywords
Schizophrenia
Brief summary
The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups.
Interventions
None listed
Sponsors
Power Life Sciences Inc.
Study design
Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of schizophrenia * Considered reliable, able to understand, and willing to perform all study procedures * Signed Written Informed Consent
Exclusion criteria
* Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug * Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * Any serious and/or unstable pre-existing medical disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of schizophrenia patients who decide to enroll in a clinical trial | 3 months |
| Rate of schizophrenia patients who remain in clinical trial to trial completion | 12 months |
Countries
United States
Contacts
Primary ContactMichael B Gill
Outcome results
None listed